CN Patent

CN111511915A — 糖原病Ia型治疗药

Assigned to Daiichi Sankyo Co Ltd · Expires 2020-08-07 · 6y expired

What this patent protects

本发明确立一种糖原病Ia型的分子治疗法。本发明为一种寡核苷酸、其药理上容许的盐或溶剂合物，所述寡核苷酸是含有与具有c.648G＞T变异的G6PC基因的cDNA互补的核苷酸序列的碱基数为15～30的寡核苷酸，且含有与具有c.648G＞T变异的G6PC基因的包含外显子5的5'末端起第82号至第92号的任一部位的区域互补的序列。本发明的医药(例如，糖原病Ia型治疗药)包含所述寡核苷酸、其医药上可容许的盐或溶剂合物。

USPTO Abstract

本发明确立一种糖原病Ia型的分子治疗法。本发明为一种寡核苷酸、其药理上容许的盐或溶剂合物，所述寡核苷酸是含有与具有c.648G＞T变异的G6PC基因的cDNA互补的核苷酸序列的碱基数为15～30的寡核苷酸，且含有与具有c.648G＞T变异的G6PC基因的包含外显子5的5'末端起第82号至第92号的任一部位的区域互补的序列。本发明的医药(例如，糖原病Ia型治疗药)包含所述寡核苷酸、其医药上可容许的盐或溶剂合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN111511915A
Jurisdiction
CN
Classification
—
Expires
2020-08-07
Drug substance claim
No
Drug product claim
No
Assignee
Daiichi Sankyo Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.